Anita Agarwal, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 7
- 4 carriers
- Office
- 1
- Since medical school
- 40 years
- Graduated 1986
Offices
1 location · West Coast Retina Medical Group Inc · 8 clinicians in this group
Hospitals listed: California Pacific Medical Center- Van Ness Campus · UCSF Health Stanyan Hospital. That is not proof they admit you there this week.
Plans that list them
7 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Agarwal’s office at (415) 972-4600 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
7 of 7 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C143103 · Current
Licensed to practise in California · since 2016 · expires 2028-06-30 · Mangalore University, Kasturba Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Tennessee 29499Medical Doctor · since 1997 · expires 2018-06-30Specialty on the licence: OphthalmologyVoluntarily RetiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
5 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Education
- Kasturba Medical CollegeMANGALORE, INDIA · 1986
Residency and fellowship
- West Virginia Univ-Surgical Retina FellowMORGANTOWN, WV · 1998–1999
- Vanderbilt University-Retina FellowNASHVILLE, TN · 1997–1998
- Univ of Florida-Opthal. ResidencyGAINESVILLE, FL · 1994–1997
- Univ of Minnesota-InternMINNEAPOLIS, MN · 1993–1994
- Pginer-Ophthalmology-ResienceyCHANDIGARH, INDIA · 1987–1990
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- UCSF Health St. Mary'S HospitalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for UCSF Health St. Mary'S Hospital
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 413 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.58 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 146.74 (92.54 to 200.93) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 51 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 220 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.3 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 102 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,363 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 2,530 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.12 to 0.53) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.02 (0.73 to 5.31) · 590 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.35) · 238 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (0.43 to 3.7) · 554 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.7 (4.19 to 21.21) · 259 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.67 (1.51 to 9.83) · 203 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 168 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.99) · 2,258 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 158 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 61 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 291 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.4 · 251 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 5.5 · 189 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 213 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.5) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12 (8.3 to 17.1) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 176 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 61 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.6 to 17.8) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 113 cases | No different | Jan 2024 – Dec 2024 |
What patients said (587 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$2,443,414
Medicare paid this office $2,443,414 for 973 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 225 | $1,412,116 | None |
| Injection, faricimab-svoa, 0.1 mg | 72 | $458,357 | None |
| Injection of drug into eye | 312 | $159,718 | $123 |
| Established patient complete exam of visual system | 824 | $131,350 | $119 |
| Imaging of retina | 928 | $57,619 | $40 |
See all 13 services
| Injection, aflibercept, 1 mg | 225 | $1,412,116 | None |
| Injection, faricimab-svoa, 0.1 mg | 72 | $458,357 | None |
| Injection of drug into eye | 312 | $159,718 | $123 |
| Established patient complete exam of visual system | 824 | $131,350 | $119 |
| Imaging of retina | 928 | $57,619 | $40 |
| Injection, ranibizumab, 0.1 mg | 23 | $47,671 | None |
| Extended exam of the back part of the eye with retinal drawing | 743 | $23,747 | $23 |
| New patient complete exam of visual system | 147 | $21,324 | $145 |
| Compounded drug, not otherwise classified | 41 | $9,944 | None |
| Photography of the retina | 218 | $8,363 | $36 |
| Established patient problem focused exam of visual system | 55 | $6,463 | $94 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 12 | $2,230 | $186 |
| Removal of eye fluid | 13 | $2,124 | $125 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 1,398 | 1,418 | 1,239 | 1,488 | 1,371 | 1,300 |
| Removal of eye fluid | 14 | – | – | – | – | 17 |
| Destruction of growth of retina using a laser | 17 | – | – | – | – | – |
| Injection of drug or substance into membrane covering eyeball | – | – | – | 14 | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
973 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 26% · Women 59% · Also on Medicaid 17% · Health risk score 1.27. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Diabetes 27% · Chronic kidney disease 23% · Coronary heart disease 22% · Atrial fibrillation 19% · Depression 16% · Cancer 15% · Heart failure 13% · COPD 8% · Stroke 8% · Dementia 6%.
The office billed $14,969,185, Medicare allowed $3,112,636 and paid $2,443,414; for 25,214 services of 43 kinds; $1,987,543 of it was for drugs given in the office and $455,871 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 973 | 25,214 | 79 | 1.27 | $14,969,185 | $2,443,414 |
| 2023 | 1,015 | 16,717 | 79 | 1.18 | $13,119,275 | $2,251,641 |
| 2022 | 1,122 | 10,369 | 79 | 1.23 | $11,264,255 | $2,034,361 |
| 2021 | 951 | 8,657 | 78 | 1.18 | $7,729,985 | $1,460,313 |
| 2020 | 1,005 | 7,852 | 79 | 1.33 | $7,451,561 | $1,371,142 |
| 2019 | 984 | 7,953 | 78 | 1.34 | $5,733,269 | $1,391,923 |
| 2018 | 1,034 | 8,601 | 79 | 1.40 | $5,227,729 | $1,555,035 |
| 2017 | 586 | 4,775 | 78 | 1.31 | $3,008,761 | $935,632 |
| 2016 | 753 | 2,531 | 75 | 1.45 | $1,495,197 | $363,716 |
| 2015 | 764 | 2,493 | 72 | 1.45 | $1,359,805 | $273,482 |
| 2014 | 798 | 2,544 | 71 | 1.43 | $1,174,002 | $208,332 |
| 2013 | 844 | 2,637 | 71 | 1.46 | $1,291,636 | $245,710 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Injection, aflibercept, 1 mg | 214 | $1,464,607 | None |
| Injection, faricimab-svoa, 0.1 mg | 25 | $215,300 | None |
| Injection of drug into eye | 313 | $160,340 | $117 |
| Established patient complete exam of visual system | 685 | $99,761 | $116 |
| Injection, ranibizumab, 0.1 mg | 27 | $62,503 | None |
| Imaging of retina | 914 | $55,064 | $37 |
| Compounded drug, not otherwise classified | 109 | $29,701 | None |
| Return visit (30+ min) | 238 | $23,499 | $93 |
| Extended exam of the back part of the eye with retinal drawing | 743 | $22,977 | $22 |
| New patient complete exam of visual system | 135 | $18,043 | $134 |
| Photography of the retina | 254 | $9,572 | $34 |
| New patient visit (45+ min) | 64 | $7,132 | $111 |
| Established patient problem focused exam of visual system | 64 | $6,183 | $78 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 13 | $1,902 | $146 |
| Injection, bevacizumab, 10 mg | 13 | $981 | None |
2022: 15 services
| Injection, aflibercept, 1 mg | 199 | $1,262,066 | None |
| Injection of drug into eye | 417 | $172,911 | $116 |
| Injection, ranibizumab, 0.1 mg | 38 | $153,922 | None |
| Established patient complete exam of visual system | 735 | $108,522 | $109 |
| Imaging of retina | 932 | $54,512 | $37 |
| Compounded drug, not otherwise classified | 196 | $54,045 | None |
| New patient complete exam of visual system | 230 | $30,945 | $135 |
| Extended exam of the back part of the eye with retinal drawing | 537 | $15,551 | $22 |
| Established patient problem focused exam of visual system | 126 | $13,210 | $78 |
| Photography of the retina | 248 | $9,276 | $33 |
| Return visit (30+ min) | 50 | $6,318 | $121 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 40 | $5,146 | $129 |
| Extended exam of the back part of the eye with optic nerve drawing | 279 | $3,461 | $11 |
| Injection of drug or substance into membrane covering eyeball | 11 | $687 | $49 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $50 | None |
2021: 13 services
| Injection, aflibercept, 1 mg | 100 | $829,031 | None |
| Injection of drug into eye | 284 | $145,429 | $117 |
| Injection, ranibizumab, 0.1 mg | 27 | $132,057 | None |
| Established patient complete exam of visual system | 762 | $116,829 | $110 |
| Compounded drug, not otherwise classified | 171 | $62,115 | None |
| Imaging of retina | 732 | $44,157 | $38 |
| New patient complete exam of visual system | 190 | $24,883 | $131 |
| Extended exam of the back part of the eye with optic nerve drawing | 604 | $12,097 | $15 |
| Photography of the retina | 233 | $9,737 | $37 |
| Established patient problem focused exam of visual system | 86 | $8,417 | $79 |
| Extended exam of the back part of the eye with retinal drawing | 204 | $4,768 | $20 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 36 | $4,547 | $123 |
| 2d ultrasound scan of eye tissue and structures | 18 | $967 | $48 |
2020: 12 services
| Injection, aflibercept, 1 mg | 135 | $784,569 | None |
| Injection of drug into eye | 427 | $142,999 | $101 |
| Injection, ranibizumab, 0.1 mg | 38 | $119,703 | None |
| Established patient complete exam of visual system | 664 | $87,079 | $108 |
| Compounded drug, not otherwise classified | 269 | $80,016 | None |
| Imaging of retina | 782 | $46,791 | $37 |
| New patient complete exam of visual system | 164 | $21,960 | $134 |
| Established patient problem focused exam of visual system | 123 | $14,709 | $76 |
| Photography of the retina | 187 | $8,693 | $42 |
| Extended exam of the back part of the eye with retinal drawing | 175 | $4,316 | $23 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 36 | $3,790 | $105 |
| Short return visit | 22 | $1,038 | $43 |
2019: 13 services
| Injection, aflibercept, 1 mg | 100 | $681,413 | None |
| Injection, ranibizumab, 0.1 mg | 70 | $209,375 | None |
| Injection of drug into eye | 321 | $139,656 | $100 |
| Established patient complete exam of visual system | 721 | $100,872 | $108 |
| Compounded drug, not otherwise classified | 240 | $69,462 | None |
| Imaging of retina | 795 | $51,702 | $37 |
| New patient complete exam of visual system | 208 | $27,787 | $134 |
| Established patient problem focused exam of visual system | 214 | $24,030 | $78 |
| Destruction of growth of retina using a laser | 12 | $8,523 | $501 |
| Photography of the retina | 156 | $7,475 | $46 |
| Examination of eye by ophthalmoscope with retinal drawing | 106 | $4,432 | $27 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 41 | $3,783 | $92 |
| Removal of eye fluid | 14 | $1,334 | $95 |
2018: 14 services
| Injection, aflibercept, 1 mg | 138 | $862,784 | None |
| Injection, ranibizumab, 0.1 mg | 51 | $219,641 | None |
| Injection of drug into eye | 421 | $143,543 | $93 |
| Established patient complete exam of visual system | 672 | $83,109 | $98 |
| Compounded drug, not otherwise classified | 267 | $65,725 | None |
| Imaging of retina | 824 | $48,521 | $34 |
| Established patient problem focused exam of visual system | 308 | $34,874 | $71 |
| New patient complete exam of visual system | 178 | $21,354 | $120 |
| Removal of membrane of retina | 11 | $12,353 | $1,029 |
| Photography of the retina | 219 | $11,960 | $51 |
| Destruction of leaking blood vessels of retina using laser | 14 | $6,751 | $307 |
| Destruction of growth of retina using a laser | 12 | $5,984 | $499 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 51 | $4,185 | $82 |
| Removal of eye fluid | 16 | $2,137 | $107 |
2017: 11 services
| Injection, aflibercept, 1 mg | 84 | $501,054 | None |
| Injection, ranibizumab, 0.1 mg | 25 | $157,294 | None |
| Injection of drug into eye | 234 | $81,450 | $98 |
| New patient complete exam of visual system | 279 | $35,739 | $128 |
| Established patient problem focused exam of visual system | 213 | $30,191 | $78 |
| Compounded drug, not otherwise classified | 126 | $29,398 | None |
| Imaging of retina | 387 | $24,248 | $38 |
| Established patient complete exam of visual system | 154 | $18,185 | $107 |
| Photography of the retina | 180 | $12,826 | $65 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 42 | $3,270 | $76 |
| Injection, bevacizumab, 10 mg | 12 | $862 | None |
2016: 17 services
| Injection, aflibercept, 1 mg | 46 | $179,497 | None |
| Injection of drug into eye | 134 | $25,224 | $85 |
| Established patient complete exam of visual system | 178 | $16,116 | $85 |
| Established patient complete exam of visual system | 321 | $16,070 | $48 |
| Injection of drug into eye | 73 | $15,737 | $72 |
| New patient complete exam of visual system | 55 | $7,437 | $135 |
| Removal of eye fluid (vitreous) between lens and retina | 13 | $7,299 | $561 |
| Imaging of retina | 181 | $7,164 | $34 |
| Injection, bevacizumab, 10 mg | 45 | $7,090 | None |
| Established patient problem focused exam of visual system | 97 | $6,853 | $62 |
| Established patient problem focused exam of visual system | 97 | $4,624 | $32 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 22 | $4,247 | $104 |
| Photography of the retina | 50 | $3,567 | $71 |
| Imaging of retina | 125 | $3,345 | $19 |
| Compounded drug, not otherwise classified | 36 | $2,948 | None |
| New patient complete exam of visual system | 31 | $1,876 | $61 |
| Photography of the retina | 55 | $807 | $14 |
2015: 19 services
| Injection, aflibercept, 1 mg | 16 | $94,873 | None |
| Established patient complete exam of visual system | 435 | $24,066 | $51 |
| Injection of drug into eye | 75 | $22,054 | $74 |
| Injection of drug into eye | 53 | $15,844 | $76 |
| Established patient complete exam of visual system | 165 | $15,071 | $82 |
| Removal of eye fluid (vitreous) between lens and retina | 14 | $7,139 | $476 |
| Established patient problem focused exam of visual system | 122 | $7,106 | $34 |
| Injection, bevacizumab, 10 mg | 41 | $6,192 | None |
| Established patient problem focused exam of visual system | 60 | $4,706 | $52 |
| Imaging of retina | 154 | $4,360 | $19 |
| Imaging of retina | 81 | $3,830 | $31 |
| New patient complete exam of visual system | 45 | $3,020 | $67 |
| Removal of recurring cataract in lens capsule using a laser | 11 | $2,410 | $219 |
| Photography of the retina | 89 | $1,591 | $17 |
| Photography of the retina | 29 | $1,477 | $51 |
| Unclassified biologics | 19 | $1,448 | None |
| New patient complete exam of visual system | 16 | $1,366 | $85 |
| 2d ultrasound scan of eye tissue and structures | 12 | $678 | $38 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 16 | $501 | $31 |
2014: 17 services
| Established patient complete exam of visual system | 502 | $30,704 | $52 |
| Injection of drug into eye | 81 | $22,639 | $68 |
| Established patient complete exam of visual system | 180 | $18,392 | $84 |
| Injection of drug into eye | 50 | $11,918 | $70 |
| Established patient problem focused exam of visual system | 116 | $7,266 | $35 |
| Injection, bevacizumab, 10 mg | 40 | $5,949 | None |
| Destruction of growth of retina using a laser | 11 | $5,844 | $390 |
| Established patient problem focused exam of visual system | 52 | $5,058 | $54 |
| Imaging of retina | 151 | $4,711 | $21 |
| New patient complete exam of visual system | 58 | $4,054 | $70 |
| Imaging of retina | 62 | $3,183 | $32 |
| Photography of the retina | 102 | $1,668 | $16 |
| Photography of the retina | 38 | $1,645 | $41 |
| Unclassified biologics | 22 | $1,575 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 13 | $1,388 | $66 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 26 | $995 | $33 |
| 2d ultrasound scan of eye tissue and structures | 12 | $413 | $34 |
2013: 18 services
| Injection, aflibercept, 1 mg | 19 | $37,078 | None |
| Established patient complete exam of visual system | 511 | $30,280 | $51 |
| Injection of drug into eye | 81 | $21,566 | $64 |
| Established patient complete exam of visual system | 155 | $15,645 | $86 |
| Injection of drug into eye | 46 | $11,358 | $71 |
| Established patient problem focused exam of visual system | 126 | $8,419 | $36 |
| New patient complete exam of visual system | 95 | $6,527 | $69 |
| Injection, bevacizumab, 10 mg | 38 | $5,606 | None |
| Established patient problem focused exam of visual system | 61 | $5,303 | $56 |
| Imaging of retina | 134 | $4,127 | $19 |
| Removal of recurring cataract in lens capsule using a laser | 15 | $3,888 | $216 |
| Photography of the retina | 148 | $2,516 | $16 |
| Imaging of retina | 57 | $2,406 | $30 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 30 | $982 | $31 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 20 | $861 | $43 |
| Photography of the retina | 41 | $774 | $19 |
| 2d ultrasound scan of eye tissue and structures | 14 | $643 | $40 |
| Exam of visual field with extended testing | 16 | $283 | $18 |
Medicaid work
$180,969 in 2024
Medicaid paid $180,969 for 908 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 116 | $102,341 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 279 | $61,360 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 177 | $8,858 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 223 | $6,283 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 113 | $2,127 |
| 2024 | 908 | 5 | 34 | $180,969 |
| 2023 | 1,318 | 9 | 48 | $370,574 |
| 2022 | 1,470 | 10 | 47 | $182,747 |
| 2021 | 838 | 7 | 31 | $50,100 |
| 2020 | 759 | 5 | 31 | $47,255 |
| 2019 | 501 | 4 | 27 | $35,766 |
| 2018 | 204 | 3 | 19 | $19,439 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 157 | $206,793 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 479 | $138,950 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 289 | $9,732 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 142 | $8,433 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 174 | $4,207 |
| Injection, bevacizumab, 10 mg | 32 | $1,148 |
| Return visit (30+ min) | 14 | $705 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 13 | $430 |
| Compounded drug, not otherwise classified | 18 | $178 |
2022
| Aflibercept injection | 144 | $91,646 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 447 | $76,723 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 310 | $6,442 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 79 | $2,350 |
| Injection, bevacizumab, 10 mg | 58 | $2,021 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 100 | $1,738 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 109 | $1,322 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 50 | $407 |
| Compounded drug, not otherwise classified | 22 | $56 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 151 | $42 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 316 | $44,541 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 181 | $3,539 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 62 | $700 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 13 | $602 |
| Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report | 89 | $510 |
| Compounded drug, not otherwise classified | 62 | $169 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 115 | $41 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 328 | $38,758 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 220 | $5,060 |
| Compounded drug, not otherwise classified | 169 | $2,140 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 26 | $1,002 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 16 | $295 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 235 | $30,931 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 189 | $4,057 |
| Compounded drug, not otherwise classified | 53 | $448 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 24 | $331 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 151 | $18,783 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 35 | $519 |
| Compounded drug, not otherwise classified | 18 | $137 |
Drugs they prescribed that Part D paid
$25,919
Pharmacies billed $25,919 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 235) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
127 generic and 108 brand-name prescriptions · $25,919 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 77 | $4,943 | $64 |
| Dorzolamide | 24 | $417 | $17 |
| Polymyxin B Sul-Trimethoprim | 34 | $254 | $7 |
Year by year
| 2024 | 235 | 89 | 0% (0) | 46% | $25,919 |
| 2023 | 266 | 101 | 0% (0) | 44% | $27,158 |
| 2022 | 188 | 81 | 0% (0) | 51% | $9,481 |
| 2021 | 191 | 73 | 0% (0) | 49% | $12,103 |
| 2020 | 224 | 57 | None | None | $16,892 |
| 2019 | 227 | 67 | None | None | $12,753 |
| 2018 | 183 | 51 | None | None | $14,973 |
| 2017 | 147 | 54 | None | 50% | $14,012 |
| 2016 | 246 | 70 | None | 47% | $24,427 |
| 2015 | 683 | 110 | 4% (25) | None | $37,337 |
| 2014 | 1,439 | 183 | 5% (76) | None | $70,163 |
| 2013 | 1,240 | 170 | 4% (46) | 22% | $91,828 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Prednisolone Acetate | 85 | $6,019 | $71 |
| Methotrexate | 13 | $810 | $62 |
| Dorzolamide | 30 | $789 | $26 |
| Timolol Maleate | 12 | $718 | $60 |
| Ketorolac Tromethamine | 18 | $709 | $39 |
| Moxifloxacin | 18 | $564 | $31 |
| Polymyxin B Sul-Trimethoprim | 26 | $249 | $10 |
2022: 5 drugs
| Prednisolone Acetate | 83 | $6,249 | $75 |
| Ketorolac Tromethamine | 13 | $335 | $26 |
| Moxifloxacin | 11 | $276 | $25 |
| Prednisone | 14 | $240 | $17 |
| Polymyxin B Sul-Trimethoprim | 28 | $220 | $8 |
2021: 4 drugs
| Prednisolone Acetate | 77 | $5,909 | $77 |
| Ketorolac Tromethamine | 14 | $360 | $26 |
| Polymyxin B Sul-Trimethoprim | 37 | $335 | $9 |
| Dorzolamide | 14 | $264 | $19 |
2020: 5 drugs
| Methazolamide | 16 | $6,250 | $391 |
| Prednisolone Acetate | 64 | $4,759 | $74 |
| Ketorolac Tromethamine | 17 | $531 | $31 |
| Polymyxin B Sul-Trimethoprim | 23 | $210 | $9 |
| Furosemide | 13 | $68 | $5 |
2019: 3 drugs
| Prednisolone Acetate | 51 | $4,712 | $92 |
| Ketorolac Tromethamine | 18 | $461 | $26 |
| Polymyxin B Sul-Trimethoprim | 29 | $284 | $10 |
2018: 4 drugs
| Prednisolone Acetate | 53 | $3,701 | $70 |
| Dorzolamide | 13 | $238 | $18 |
| Timolol Maleate | 14 | $133 | $10 |
| Polymyxin B Sul-Trimethoprim | 17 | $132 | $8 |
2017: 2 drugs
| Prednisolone Acetate | 50 | $4,164 | $83 |
| Polymyxin B Sul-Trimethoprim | 23 | $183 | $8 |
2016: 4 drugs
| Prednisolone Acetate | 40 | $3,104 | $78 |
| Methotrexate | 24 | $2,487 | $104 |
| Alphagan P | 11 | $2,432 | $221 |
| Prednisone | 11 | $103 | $9 |
2015: 23 drugs
| Prednisolone Acetate | 47 | $3,290 | $70 |
| Methotrexate | 19 | $2,781 | $146 |
| Donepezil | 12 | $712 | $59 |
| Brimonidine | 15 | $706 | $47 |
| Gabapentin | 19 | $562 | $30 |
| Buspirone | 13 | $545 | $42 |
| Metoprolol | 15 | $412 | $27 |
| Atorvastatin | 17 | $401 | $24 |
| Pravastatin | 15 | $354 | $24 |
| Potassium Chloride | 14 | $211 | $15 |
| Omeprazole | 18 | $175 | $10 |
| Metformin | 12 | $172 | $14 |
| Levothyroxine | 16 | $164 | $10 |
| Timolol Maleate | 13 | $148 | $11 |
| Prednisone | 14 | $123 | $9 |
| Warfarin | 14 | $106 | $8 |
| Metoprolol | 11 | $105 | $10 |
| Simvastatin | 14 | $94 | $7 |
| Amlodipine Besylate | 17 | $90 | $5 |
| Furosemide | 12 | $86 | $7 |
| Enalapril Maleate | 15 | $78 | $5 |
| Ranitidine | 16 | $64 | $4 |
| Hydrochlorothiazide | 14 | $46 | $3 |
2014: 46 drugs
| Prednisolone Acetate | 58 | $4,129 | $71 |
| Lyrica | 11 | $3,799 | $345 |
| Methotrexate | 21 | $3,778 | $180 |
| Acetazolamide | 12 | $2,869 | $239 |
| Valacyclovir | 14 | $2,351 | $168 |
| Fenofibrate | 16 | $1,446 | $90 |
| Metoprolol | 36 | $1,260 | $35 |
| Brimonidine | 14 | $1,095 | $78 |
| Gabapentin | 42 | $1,086 | $26 |
| Mycophenolate Mofetil | 11 | $1,085 | $99 |
| Pravastatin | 45 | $1,064 | $24 |
| Atorvastatin | 24 | $794 | $33 |
| Lansoprazole | 11 | $620 | $56 |
| Losartan | 19 | $608 | $32 |
| Hydrocodone-Acetaminophen | 24 | $559 | $23 |
| Valsartan-Hydrochlorothiazide | 11 | $515 | $47 |
| Simvastatin | 62 | $476 | $8 |
| Timolol Maleate | 17 | $449 | $26 |
| Donepezil | 16 | $446 | $28 |
| Dorzolamide | 11 | $406 | $37 |
| Clopidogrel | 16 | $399 | $25 |
| Omeprazole | 43 | $389 | $9 |
| Potassium Chloride | 17 | $344 | $20 |
| Klor-Con M20 | 13 | $339 | $26 |
| Levothyroxine | 14 | $282 | $20 |
| Prednisone | 29 | $276 | $10 |
| Enalapril Maleate | 28 | $238 | $9 |
| Lisinopril | 31 | $238 | $8 |
| Warfarin | 24 | $229 | $10 |
| Metoprolol | 26 | $213 | $8 |
| Clonazepam | 23 | $206 | $9 |
| Paroxetine | 17 | $202 | $12 |
| Ranitidine | 27 | $200 | $7 |
| Amlodipine Besylate | 23 | $200 | $9 |
| Metformin | 23 | $189 | $8 |
| Sertraline | 21 | $155 | $7 |
| Lisinopril-Hydrochlorothiazide | 19 | $132 | $7 |
| Acetaminophen-Codeine | 20 | $128 | $6 |
| Tramadol | 25 | $123 | $5 |
| Hydrochlorothiazide | 22 | $119 | $5 |
| Furosemide | 27 | $115 | $4 |
| Allopurinol | 16 | $102 | $6 |
| Terazosin | 12 | $86 | $7 |
| Amitriptyline | 18 | $83 | $5 |
| Trazodone | 21 | $71 | $3 |
| Dicyclomine | 11 | $44 | $4 |
2013: 34 drugs
| Methotrexate | 37 | $3,897 | $105 |
| Lantus | 15 | $3,231 | $215 |
| Detrol La | 13 | $2,660 | $205 |
| Atorvastatin | 47 | $1,709 | $36 |
| Prednisolone Acetate | 58 | $1,296 | $22 |
| Fenofibrate | 18 | $1,010 | $56 |
| Metoprolol | 31 | $990 | $32 |
| Potassium Chloride | 20 | $655 | $33 |
| Dorzolamide-Timolol | 14 | $532 | $38 |
| Omeprazole | 25 | $527 | $21 |
| Losartan | 20 | $490 | $24 |
| Pravastatin | 27 | $377 | $14 |
| Simvastatin | 42 | $353 | $8 |
| Lisinopril | 36 | $347 | $10 |
| Levothyroxine | 15 | $346 | $23 |
| Carvedilol | 30 | $341 | $11 |
| Gabapentin | 23 | $307 | $13 |
| Donepezil | 11 | $299 | $27 |
| Warfarin | 21 | $261 | $12 |
| Lisinopril-Hydrochlorothiazide | 30 | $259 | $9 |
| Amlodipine Besylate | 39 | $254 | $7 |
| Hydrocodone-Acetaminophen | 14 | $239 | $17 |
| Tamsulosin | 11 | $230 | $21 |
| Prednisone | 20 | $226 | $11 |
| Ranitidine | 18 | $212 | $12 |
| Furosemide | 23 | $212 | $9 |
| Allopurinol | 18 | $208 | $12 |
| Sertraline | 25 | $193 | $8 |
| Tramadol | 20 | $171 | $9 |
| Hydrocortisone | 11 | $154 | $14 |
| Hydrochlorothiazide | 19 | $150 | $8 |
| Metoprolol | 21 | $135 | $6 |
| Terazosin | 14 | $100 | $7 |
| Trazodone | 12 | $67 | $6 |
Money from drug and device companies
$75 in 2023
| 2023 | 2 | 2 | None | $75 |
| 2022 | 1 | 3 | None | $69 |
| 2021 | 2 | 2 | None | $47 |
| 2020 | 1 | 1 | None | $25 |
| 2019 | 2 | 2 | None | $50 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bausch & Lomb Americas | Envista Mx60 Iol | $47 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $27 | 1 payment
|
See all 2 published payments
| Bausch & Lomb Americas | Meals · 2023-11-10 | Envista Mx60 Iol | $47 |
| Regeneron Healthcare Solutions | Meals · 2023-09-22 | Eylea Hd | $27 |
See earlier years (2022, 2021, 2020, 2019)
2022: $69
| EyePoint Pharmaceuticals US | Dexycu | $69 | 3 payments
|
2021: $47
| Genentech USA | Lucentis | $23 | 1 payment
|
| EyePoint Pharmaceuticals US | Dexycu | $23 | 1 payment
|
2020: $25
| Genentech USA | Lucentis | $25 | 1 payment
|
2019: $50
| Novartis Pharmaceuticals | None | $26 | 1 payment
|
| Genentech USA | Lucentis | $25 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 70.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1508940628
- Licence
- CA C143101, CA C143103, TN MD29499California C143103: Current · expires 2028-06-30Tennessee 29499: Voluntarily Retired
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1445 Bush St, San Francisco, CA, 94109
- NPI first listed
- 2006-10-25
- NPI last updated
- 2020-08-21
- NPI record certified
- 2020-08-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 100 Tamal Plz Ste 120, Corte Madera, CA, 94925 · 400 30th St Ste 402, Oakland, CA, 94609 · 101 S San Mateo Dr Ste 306, San Mateo, CA, 94401 · 1981 N Broadway Ste 265, Walnut Creek, CA, 94596
This office lists an electronic records connection.